ORKA (Oruka Therapeutics) Current Deferred Taxes Liabilities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
12 GF Score
Price $109.71
! 2 Warning Signs
View Full Analysis

What is Oruka Therapeutics Current Deferred Taxes Liabilities?

Oruka Therapeutics ORKA -2.97% 12 Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus rates ORKA with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Oruka Therapeutics's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Oruka Therapeutics Current Deferred Taxes Liabilities Related Terms

Oruka Therapeutics Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Current Deferred Taxes Liabilities Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
Current Deferred Taxes Liabilities
0.00 0.00

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORKA
12GF Score
Oruka Therapeutics Inc ORKA
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Oruka Therapeutics (ORKA) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Current Deferred Taxes Liabilities too high?
Oruka Therapeutics' current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Oruka Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Current Deferred Taxes Liabilities compare to DNTH and SRRK?
Oruka Therapeutics' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Oruka Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
12GF Score

Get the complete analysis for ORKA

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$109.71
Price